U.S. Markets open in 3 hrs 56 mins

How AstraZeneca Is Advancing Its Oncology Portfolio in 2019

Margaret Patrick
How AstraZeneca Is Advancing Its Oncology Portfolio in 2019

On March 28, AstraZeneca (AZN) issued a press release announcing its collaboration with Daiichi Sankyo for the development and commercialization of trastuzumab deruxtecan, an investigational therapy currently being evaluated for multiple HER2-expressing cancers.